Oppenheimer lowered the firm’s price target on BridgeBio Oncology (BBOT) to $22 from $23 and keeps an Outperform rating on the shares after its wider than expected loss. The firm has also updated its operating expense estimates based on guidance from management, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology reports Q3 EPS ($1.03), consensus (34c)
- BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating
- BridgeBio Oncology announces new preclinical data on BBO-11818 study
- BridgeBio Oncology management to meet with Oppenheimer
- BridgeBio Oncology initiated with an Outperform at Leerink